Welcome to our website

Our website aims to provide information and insight into the life of an individual with Myasthenia Gravis.

The site will provide a description of the disease and its causes, its symptoms and treatment, aswell as an outlook to what the future might hold.

Histology of a neuromuscular junction

Myasthenia gravis is an autoimmune neuromuscular disorder, affecting 1 person in every 10,000 in the UK. It can start at any age from childhood onwards and the chance of developing it increases with age.  The average age onset in females is 28 and in males is 42 years of age- however, in 10%  of cases myasthenia gravis begins in childhood.

The defining feature of myasthenia gravis is painless muscle weakness that fatigues, with characteristic periods of exacerbation and remission. Symptoms typically get worse towards the end of the day and after exercise. It was first described in medical reports as early as 1672, but did not become named until the 1880's.

The prognosis of myasthenia gravis is generally good, and due to the array of therapies that are now available more than 90% of sufferers can return to an almost normal life.


Banner image courtesy of flikr  under the Creative Commons license.

Image courtesy of flikr under the Creative Commons license

Latest News

Bayhill's BHT-3034 receives FDA IND clearance for treatment of Myasthenia gravis

01/03/2011 10:00
Bayhill's Therapeutics novel BHT-3034 vaccine immunotherapy has been cleared by FDA for treatment of patients with myasthenia gravis. For further...

Rituximab Effective in Myasthenia Gravis

14/04/2010 10:00
A research group from Yale University have found promising evidence that the anti-CD20 antibody decreases B-cell activation, markedly...

The case of Baby RB: Congenital Myasthenic Syndrome

10/11/2009 10:00
Baby RB, born with CMS meaning he could not breathe unaided, was allowed to die after his father withdrew his opposition to a high...

New Treatment Boosts Muscle Function in MG

20/08/2007 10:00
A novel treatment produced by researchers at Hadassah Hebrew University Medical Center in Jerusalem, has been...